We examined the phenotypic characteristics, lowest plasma sterol and triglyceride concentrations and cholestanol:cholesterol ratio were achieved molecular genetics and optimal pharmacological treatment of cerebrotendinous xanthomatosis (CTX) with the combination of chenodeoxycholic acid (CDCA) 750 mg/day, a primary bile acid, and simvain an English family with combined hyperlipidaemia. The proband presented in adulthood with classical statin 40 mg/day, an inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. CDCA alone clinical characteristics of CTX, a greater than tenfold elevation in plasma cholestanol and combined and simvastatin alone significantly lowered plasma cholestanol concentration, but the decrease was hyperlipidaemia. His brother also had typical features of CTX without the presence of dyslipidaemia.
Summary
We examined the phenotypic characteristics, lowest plasma sterol and triglyceride concentrations and cholestanol:cholesterol ratio were achieved molecular genetics and optimal pharmacological treatment of cerebrotendinous xanthomatosis (CTX) with the combination of chenodeoxycholic acid (CDCA) 750 mg/day, a primary bile acid, and simvain an English family with combined hyperlipidaemia. The proband presented in adulthood with classical statin 40 mg/day, an inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. CDCA alone clinical characteristics of CTX, a greater than tenfold elevation in plasma cholestanol and combined and simvastatin alone significantly lowered plasma cholestanol concentration, but the decrease was hyperlipidaemia. His brother also had typical features of CTX without the presence of dyslipidaemia.
greater with the former. After 1 year there was significant improvement in both cognitive and motor Genotyping revealed that the two brothers were compound heterozygotes for a novel missense mutafunction with regression of tendon xanthomata on computerized tomography. We conclude that CTX tion in exon 2 (R94Q) and for a recently described nonsense mutation in exon 5, of the sterol 27-in this English pedigree is probably due to compound mutant alleles in CYP27, that combined hyperlipidahydroxylase gene (CYP27). Analysis of all available family members revealed that hyperlipidaemia did emia in this family is unrelated to CTX, and that this complicated condition responds optimally to not co-segregate with the presence of a CYP27 mutant allele. Trial of therapy showed that the the combination of CDCA and simvastatin.
Introduction
Cerebrotendinous xanthomatosis (CTX) is a rare of bile acids and increased production of cholestanol,3,4 the 5a-dihydro derivative of cholesterol, autosomal recessive disorder which results in disabling neurological disease, tendon xanthomata, which accumulates in plasma and in all tissues,4 notably the central nervous system and tendon cataracts and premature atherosclerosis.1 The metabolic defect in CTX is due to underactivity of sheaths. Affected patients almost invariably have normal plasma lipid levels.5 None of the cases so 27-hydroxylase (EC 1.14.13.15), a mitochondrial enzyme member of the cytochrome P450s that far reported have been from an English pedigree. Treatment of CTX relies on pharmacological catalyses the oxidation of the side-chain of sterol intermediates in the pathway for converting cholesinhibition of the formation of cholestanol to decrease its concentration in plasma and ultimately regress or terol to bile acids.2 There is reduced hepatic synthesis stabilize organ damage.1 The most effective agent is or xanthomata. Achilles tendon xanthomata were examined by computerized tomography (CT) scan. reportedly chenodeoxycholic acid (CDCA), which expands the bile acid pool and reciprocally decreases cholestanol synthesis.6,7 There may also be benefit Pedigree study from inhibiting 3-hydroxy-3-methyl-glutaryl coenOf fifteen close family members, thirteen consented zyme A (HMGCoA) reductase with a statin, but to be examined. A 42-year-old brother (Study number studies have produced conflicting results.8-10 The #240-13; Pedigree number II-6) had abnormal clintherapeutic role of simvastatin, a highly effective ical findings, and these are compared with the HMGCoA reductase inhibitor,11 has not been estabproband in Table 1 . The remainder of the family lished.10 In CTX the presence of hyperlipidaemia, members did not show the phenotypic characteristics however, may justify using statins in combination of CTX. The maternal grandparents were first cousins, therapy. 12 but there was no other evidence of consanguinity. Since untreated CTX is a fatal disorder,1 early
There was a family history of coronary artery disease, detection is critical, and molecular genetics offers three maternal relations having died prematurely the definitive method for screening at-risk patients. 13 from myocardial infarction as well as the paternal Several mutant alleles of the sterol 27-hydroxylase grandfather at 62 years. gene (CYP27) thought to be responsible for CTX have been characterized,13 mostly in patients of Jewish Therapeutic regimens origin.14,15 The condition is probably genetically heterogenous12-16 and the full range of mutations has
The proband and his affected brother were both yet to be identified. treated for three consecutive 4-month periods In the present study, we describe the first cases of with simvastatin (40 mg/day) alone, simvastatin CTX in an English pedigree that also appeared to (40 mg/day) plus CDCA (750 mg/day), and CDCA exhibit combined hyperlipidaemia. We aimed to (750 mg/day) alone. Both were prescribed an isocalexamine the optimal therapy, with specific reference oric, fat-modified diet throughout the treatment to the use of simvastatin, and to characterize the periods, with monthly checks on compliance by molecular defect of the disorder.
packet count and on drug safety by clinical enquiry and measurement of liver and muscle enzymes.
Since simvastatin+CDCA was subsequently shown to achieve the lowest cholestanol levels, both patients
Methods
were treated with this drug regimen for a further 12 months, at the end of which neurological assessment,
Case report
psychometry, EEG, EMG, brain MRI and CT scan of A 40-year-old man (Study number #240-9; Pedigree both Achilles tendons were repeated. number II-5) presented to a neurologist with difficulty in walking, and swelling of the ankles and wrists.
Chemical analysis
His mother reported that over the last 5 years he had been progressively unsteady on his feet, and Venous blood was collected after a 12 h fast into tubes containing Na 2 EDTA (final concentration that memory, writing and reading abilities had deteriorated significantly. He had done poorly at school 1 mg/ml) for lipid, lipoprotein and cholestanol analyses. A biopsy of the left Achilles tendon was also and had undergone removal of juvenile cataracts. Examination revealed large Achilles and extensor obtained from the proband for sterol analysis. Because following therapy plasma cholestanol takes tendon xanthomata, truncal ataxia, hyperreflexia, bilateral Babinski responses and vibration loss at the approximately 12 weeks to approach a nadir,10 blood was only sampled on three separate occasions during ankles. Cognition and mental function were impaired, with grossly abnormal verbal and visual the fourth month of the three periods of treatment. The plasma concentration of cholesterol was recall, and an IQ of 65 on psychometry. Body mass index was 25 kg/m2 with normal blood pressure, measured by the CHOD-PAP enzymic colorimetric method (Boehringer); interassay CV<3.5%. Plasma urinalysis, liver enzymes, thyroid hormones and plasma glucose. Chest X-ray and resting electrocartriglyceride was also measured enzymically (Wako Chemicals); interassay CV<3%. High-density lipodiogram were normal. An electroencephalogram (EEG) showed diffuse excess of slow-wave activity at protein (HDL) cholesterol was assayed after precipitation of apolipoprotein B with heparin manganese/ 7-8 c/s. Electromyography (EMG) revealed a generalized demyelinating neuropathy, but no axonal dextran sulphate. Low-density lipoprotein (LDL) cholesterol was derived from the Friedewald formula. damage. Magnetic resonance imaging (MRI) of the brain showed bilateral low attenuation areas in the After hydrolysis and extraction, plasma cholestanol was quantified as the ketone derivative by gas dentate nuclei, but no evidence of diffuse atrophy by guest on September 23, 2016 Downloaded from chromatography (GC) using a Hewlett Packard 5890
Results
Series II Gas Chromatograph fitted with flame ioniza- Table 1 confirms that the proband (#240-II-5) and tion detector.17 Coprostanol (Steraloids Ltd) was used his brother (#240-II-6) had classical clinical features as the internal standard. The concentration of plasma of CTX with extreme elevation in plasma cholestanol cholestanol was determined by comparing peak concentration. In the proband, the cholesterol and height ratios of cholestanol to coprostanol in the cholestanol contents of the Achilles tendon biopsy plasma sample with standards. The ketones were were 49.7 and 3.5 mg/mg wet weight, respectively, separated using an HP17 series 530 column (15 m consistent with other cases of CTX.1 Patient #240-IIlong), oven temperature 240°C, detector temperature 5 had combined hyperlipidaemia according to newly 280°C and helium as the carrier gas. The cholestanol published definitions,18 but #240-II-6 had normal method had a between assay CV of 7.4%. The plasma lipid and lipoprotein concentrations. In concentrations (mg/mg wet weight) of cholestanol neither patient were the plasma concentrations of and cholesterol in the biopsy of the Achilles tendon phytosterols elevated.17 were measured (in patient #240-II-6) by the same Table 2 shows the plasma sterol, triglyceride and method as described for plasma. To exclude phyto-HDL cholesterol concentrations and the cholestanol: sterolaemia, plasma beta-sitosterol and campesterol cholesterol ratio in patients #240-II-5 and #240-II-6 concentrations were measured as the underivatised in response to treatment with simvastatin alone, sterols by the same method as cholestanol, excluding simvastatin+CDCA and CDCA alone; normal values the ketone derivatization stage.17
for plasma cholestanol and cholestanol:cholesterol ratio in 10 control subjects were 0.33(±SEM 0.07) mg/dl and 0.17(±0.05)%, respectively. In
Analysis of mutations in CYP27
patient #240-II-5, simvastatin achieved significant Genomic DNA was extracted from blood leucocytes reductions in mean plasma cholesterol (−37%) and in all subjects. All exons and the 5∞ flanking region of CYP27 in index case #240-II-5, were PCR-ampli- cholestanol (−44%); the mean cholestanol:cholesmalities resolved significantly. These changes were paralleled by improvements in EEG and EMG abnorterol ratio also fell by 14%, but this failed to reach significance. The addition of CDCA to simvastatin malities. MRI of the brain showed some resolution of the low attenuation areas in the dentate nuclei, resulted in further decreases in plasma cholestanol (−82%), cholestanol:cholesterol ratio (−74%) and although the change was barely discernible. Repeat CT scan of the Achilles tendons did, however, show triglyceride (−53%), but the mean fall in cholesterol was less than with simvastatin alone. With CDCA evidence of regression of xanthomata (Figure 1 ). His brother (#240-II-6) showed less dramatic improvealone, there was a significant fall in cholestanol (−60%), triglyceride (−46%) and the cholestanol:-ment in mental function, but the tendon xanthomata also regressed on CT scan, and he was free of cholesterol ratio (−58%), but these were all less than with combination therapy and there was no convulsions for 2 years with some resolution of EEG changes. significant change in cholesterol. HDL cholesterol concentrations did not change significantly with any SSCP analysis of all exons and the 5∞-region of CYP27 in the index case revealed abnormal band of the regimens. Only CDCA+simvastatin dropped the cholestanol concentration and ratio to a level shifts in exons 2 and 5. The band shift in exon 2 has not been observed before, and that in exon 5 that was not significantly different from normal values. In patient #240-II-6, significant decreases in was identical to a previously characterized Afrikaner mutation.16 Direct sequence analysis of PCR-ampliplasma lipids were seen with all agents. The mean reductions in plasma cholestanol and cholestanol:chfied genomic DNA from the same patient revealed a novel missense mutation in exon 2 (G to A olesterol ratio, with simvastatin, simvastatin+CDCA and CDCA alone, were (cholestanol) −62%, −84% transversion which is expected to result in an arginine (CGG) to glutamine (CAG) substitution in codon 94 and −66%, and (ratio) −25%, −76% and −64%, respectively. The pattern of fall in plasma sterol designated R94Q). Figure 2 illustrates the method for detection of the mutant alleles of CYP27 in family levels in this patient was similar to #240-II-5. Compliance with the drug regimens was >95% and #240. Figure 2a shows the abnormal band shifts in exon 2 for #240-I-2, #240-I-3, #240-II-1, 240-II-2, no untoward side-effects were noted in either patient.
After 1 year of treatment with simvastatin+CDCA, 240-II-5 and 240-II-6. Figure 2b shows the results of the direct detection method for the Afrikaner mutapatient #240-II-5 showed dramatic improvement in mental and physical abilities. alleles in the family members examined. Table 3 27-hydroxylase.2 Since the synthesis of bile acids is regulated by the quantity that returns to the liver in compares the plasma sterol concentrations and the cholestanol:cholesterol ratios with the allelic distributhe enterohepatic circulation,20 the reduced formation of bile acids in CTX results in increased convertion of the G to A transversion in exon 2 and the A to T transversion in exon 5. It is evident that the two sion of cholesterol to bile-acid precursors and simultaneous production of cholestanol.3,4 Although cases of CTX were compound heterozygotes for the mutant alleles. The remainder of the family members we did not measure biliary or plasma bile alcohol concentrations in the present study, we would expect also had normal plasma cholestanol concentrations and cholestanol:cholesterol ratios, in spite of some these to be markedly increased in both the affected patients.10,21,22 The precise mechanism for overprodbeing heterozygotes for a CYP27 mutation. Several other members of this family showed combined uction of cholestanol in CTX has been disputed. 3, [23] [24] [25] Cholestanol is derived from cholesterol via 4-hyperlipidaemia18 which did not co-segregate with the CYP27 mutant alleles (Table 3) .
cholesten-3-one. This precursor of cholestanol may be synthesized directly from cholesterol or indirectly by 7a-dehydroxylation of 7a-hydroxy-4-cholesten-3-one,3 an early precursor of bile acids. The response Discussion of our patients to the drug regimens suggest that both the direct and indirect pathways of cholestanol We have described the first cases of CTX in an English family, and the optimal mode of therapy and biosynthesis were operational: simvastatin would have specifically decreased cholesterol synthesis by genetic mutations responsible for this disorder. Both affected individuals were compound heterozygotes inhibiting HMGCoA reductase,11 and CDCA would have predominantly decreased the production of 7a-for mutations in exons 2 (R94Q) and 5 (stop 251) of CYP27. We confirm that sustained reduction in hydroxy-4-cholesten-3-one by inhibiting cholesterol 7a-hydroxylase.20 The clinical manifestations of CTX plasma cholestanol may in some cases dramatically improve clinical outcome6 and regress tendon xanthoare due to the spatial effects of xanthomatous deposits, comprising cholestanol and cholesterol, mata.9 Consistent with the recent report of Kuriyama et al. 12 we also propose that the best treatment for and to demyelination of neuronal tissue resulting from replacement of cholesterol by cholestanol in this condition is the combination of a statin and CDCA. This is particularly relevant in the proband nerve myelin.1,6 Central nervous system involvement has also been shown to result from increased perwho, exceptionally for a case of CTX, exhibited combined hyperlipidaemia.1 meability of the blood-brain barrier to plasma lipoproteins.7 Previous analysis of plasma lipids and There is no doubt that patients #240-II-5 and #240-II-6 had classical CTX.1 The diagnostic features lipoproteins in CTX families of Druze origin revealed the absence of any measurable effect of the presence were the typical neurological findings, tendon xanthomata, premature cataracts and markedly elevated of a CYP27 mutant allele on these parameters.5 In the family analysed here, we have excluded the plasma and tissue cholestanol concentrations. Dementia and grossly abnormal neurological signs possibility of co-segregation of hypercholesterolaemia or hypertriglyceridaemia with the presence of a have been described previously even in the absence of ostensible brain lesions on MRI or CT scan.1, 6 The mutant CYP27 allele. We may therefore conclude that the proband's combined hyperlipidaemia was clinical features of the two cases confirm that CTX is phenotypically heterogenous,1,6 but the basis for unrelated to the metabolic defect in CTX. These results demonstrate the inherent advantage of family this remains undefined. Hyperlipidaemia is not a consistent finding in CTX.1 The combined hyperstudies as compared to that of unrelated individuals having CTX. In addition, they further support our lipidaemia in the proband may have been due to familial combined hyperlipidaemia, given the lipid conclusion that the presence of a CYP27 mutant allele does not affect the plasma concentration of results in the remainder of the pedigree and the family history of premature atherosclerosis. 19 The routinely measured lipids and lipoproteins.5 Since CTX is an autosomal recessive disorder, it two important differential diagnoses at presentation were familial hypercholesterolaemia and phytois most prevalent in highly inbred populations. [13] [14] [15] Significant advances in the understanding of the sterolaemia,1,17 but these were excluded by the neurological involvement, absence of significant molecular basis for CTX followed the histochemical identification of deficiency in the sterol hypercholesterolaemia or premature coronary artery disease in the pedigree, and normal plasma plant 27-hydroxylase,2 cloning of its cDNA,26 characterization of the structure of CYP2714 and identification of sterol levels.
The metabolic lesion in CTX is a block in the several novel mutations. Dutch origin, an adenosine to thymidine transversion of treatment was insufficiently long to maximally mobilize the large tissue pools of cholestanol.10 in exon 5 of the gene was previously shown to result in a premature termination codon,16 a mutation also Treatment of hypercholesterolaemia per se may reduce tissue deposition of cholesterol,29 but the demonstrated in this English pedigree. The additional missense mutation in exon 2 (R94Q) was identified degree of change recorded in the proband is unlikely to have accounted for the regression of tendon as a band shift in SSCP, but did not apparently create or eliminate a restriction site. In vitro expression xanthomata. The improvement in combined hyperlipidaemia in the proband with simvastatin is likely to studies should show whether this new mutation impairs enzyme activity. Whether the various mutant have been due to the effect of a reduced intrahepatic cholesterol pool to increase LDL receptors as well alleles determine the phenotypic expressions and response to therapy also warrants examination. It is as to a decrease in the secretion of apolipoprotein B.11,30 Turnover studies will be required to dissect also interesting to speculate whether the presence of stop 251 in the present pedigree and in Afrikaners the relative importance of each of the two treatment modalities on plasma lipids and lipoproteins in the reflects a gene flow between England, the Netherlands and South Africa. Elucidation of the two affected brothers reported here, who may differ in respect to the presence of combined hyperlipidmolecular basis of CTX in the Netherlands, where a relatively large number of CTX cases were reported, aemia. Our study does have important practical implicais essential and may shed more light on this matter.
The treatment of CTX is based on pharmacological tions. The diagnosis of CTX must be considered in all patients with neurological dysfunction, tendon inhibition of the hepatic production of cholestanol, in order to decrease its plasma concentration to a xanthomata and normal or mild elevation of plasma lipids. The most efficacious treatment to reverse or level below which there is net and sustained efflux of cholestanol from tissues.6,8-10 The most widely stabilize end-organ damage is simvastatin plus CDCA, especially in the presence of concomitant recommended approach is to restore the bile-acid pool with CDCA,6,10 thereby inhibiting 7a-hydroxycombined hyperlipidaemia, since the risk of premature atherosclerosis is increased in both these lase,20 the rate-limiting enzyme for bile-acid synthesis. Another approach is to decrease selectively conditions.1, 19 In patients without concomitant hyperlipidaemia, treatment should start with CDCA,6 with the input of cholesterol into the bile-alcohol pool by competitively inhibiting HMGCoA reductase, the the addition of a statin if normal plasma levels of cholestanol are not achieved by 6 months or if an rate-limiting enzyme for cholesterol synthesis, with a statin.8,9 CDCA alone has been shown to significatherogenic lipid profile develops.12 In all patients with CTX and hyperlipidaemia, we would recomantly reduce plasma cholestanol and to dramatically improve neurological symptoms and signs,6 but this mend combination treatment with CDCA and a statin. Molecular characterization of mutations in was not paralleled by regression of tendon xanthomata. The dose of CDCA employed in the present CYP27 is useful in making a definitive diagnosis of CTX, this being particularly relevant for presymptostudy was similar to that of Salen et al.10 but higher than used by Nakamura et al.,9 which may account matic screening and for offering genetic counselling to highly inbred populations.13 for differences in the efficacy of this agent in reducing plasma cholestanol. By contrast to Kuriyama et al., 12 we did not find that CDCA alone induced an
